12/15-Lipoxygenase inhibitor baicalein suppresses PPARγ expression and nuclear translocation induced by cerebral ischemia/reperfusion

Brain Research

Volumn 1307, Issue , 2010, Pages 149-157

  Xu, Yan Wei ^a   Sun, Li ^a   Liang, Hao ^a   Sun, Guo Min ^a   Cheng, Yan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Baicalein; GW9662; Ischemia reperfusion; PPAR (peroxisome proliferator activated receptor ); Rosiglitazone; Translocation

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; BAICALEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN TISSUE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG INHIBITION; GENE TRANSLOCATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; UPREGULATION;

ANILIDES; ANIMALS; ANTIOXIDANTS; CELL NUCLEUS; CEREBRAL CORTEX; CYTOSOL; DISEASE MODELS, ANIMAL; FLAVANONES; HYPOGLYCEMIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; PPAR GAMMA; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; THIAZOLIDINEDIONES; TIME FACTORS; UP-REGULATION;

ANIMALIA; RATTUS;

EID: 70749160209     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.10.038     Document Type: Article

References (37)

1. Altmann R., Hausmann M., Spöttl T., Gruber M., Bull A.W., Menzel K., Vogl D., Herfarth H., Schölmerich J., Falk W., and Rogler G. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells. Biochem. Pharmacol. 74 (2007) 612-622 (Pubmed: 17604003)
2. Berry A., Balard P., Coste A., Olagnier D., Lagane C., Authier H., Benoit-Vical F., Lepert J.C., Séguéla J.P., Magnaval J.F., Chambon P., Metzger D., Desvergne B., Wahli W., Auwerx J., and Pipy B. IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. Eur. J. Immunol. 37 (2007) 1642-1652 (Pubmed: 17458857)
3. Boyle P.J. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am. J. Med. 120 (2007) S12-S17 (Pubmed: 17826041)
4. Bogazzi F., Russo D., Locci M.T., Chifenti B., Ultimieri F., Raqqi F., Viacava P., Cecchetti D., Cosci C., Sardella C., Acerbi G., Gasperi M., and Martino E. Peroxisome proliferator-activated receptor (PPAR) gamma is highly expressed in normal human pituitary gland. J. Endocrinol. Invest. 28 (2005) 899-904 (Pubmed:16419492)
5. Chabane N., Zayed N., Benderdour M., Martel-Pelletier J., Pelletier J.P., Duval N., and Fahmi H. Human articular chondrocytes express 15-lipoxygenase-1 and -2: potential role in osteoarthritis. Arthritis Res. Ther. 11 (2009) R44 (Pubmed: 19296842)
6. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., and Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 530 (2006) 70-80 (Pubmed:16386242)
7. Han J.L., Ding R.Y., Zhao L., Ren Z., and Jiang X.J. Rosiglitazone attenuates allergic inflammation and inhibits expression of galectin-3 in a mouse model of allergic rhinitis. J. Int. Med. Res. 36 (2008) 830-836 (Pubmed: 18652780)
8. Heydeck D., Thomas L., Schnurr K., Trebus F., Thierfelder WE., Ihle J.N., and Kuhn H. Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15-lipoxygenase activity: evidence for the involvement of transcription factor STAT6. Blood 92 (1998) 2503-2510 (Pubmed: 9746791)
9. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., and Glass C.K. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 400 (1999) 378-382 (Pubmed: 10432118)
10. Hunter R.L., Choi D.Y., Ross S.A., and Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci. Lett. 432 (2008) 198-201 (Pubmed: 18207323)
11. Kielian T., Syed M.M., Liu S., Phulwani N.K., Phillips N., Wagoner G., Drew P.D., and Esen N. The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses. J. Immunol. 180 (2008) 5004-5016 (Pubmed: 18354226)
12. Ko G.J., Kang Y.S., Han S.Y., Lee M.H., Song H.K., Han K.H., Kim H.K., Han J.Y., and Cha D.R. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant 23 (2008) 2750-2760 (Pubmed: 18388116)
13. Kuhn H. Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)XY-5Z, 8Z, 11Z, 13E-eicosatetraenoic acid and 13-hydro(pero)XY-9Z,11E-octadecadienoic acid. Prog. Lipid Res. 35 (1996) 203-226 (Pubmed: 9082450)
14. Kuhn H., Walther M., and Kuban R.J. Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat. 68-69 (2002) 263-290 (Pubmed: 12432923)
15. Lapchak P.A., Maher P., Schubert D., and Zivin J.A. Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 150 (2007) 585-591 (Pubmed: 17942241)
16. Limor R., Sharon O., Knoll E., Many A., Weisinger G., and Stern N. Lipoxygenase-derived metabolites are regulators of peroxisome proliferator-activated receptor gamma-2 expression in human vascular smooth muscle cells. Am. J. Hypertens. 21 (2008) 219-223 (Pubmed: 18202670)
17. Li F.Q., Wang T., Pei Z., Liu B., and Hong J.S. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons. J. Neural. Transm. 112 (2005) 331-347 (Pubmed: 15503194)
18. Li Q., Cheon Y.P., Kannan A., Shanker S., Baqchi I.C., and Baqchi M.K. A novel pathway involving progesterone receptor, 12/15-lipoxygenase-derived eicosanoids, and peroxisome proliferator-activated receptor gamma regulates implantation in mice. J. Biol. Chem. 279 (2004) 11570-11581 (Pubmed: 14688261)
19. Li Y., Maher P., and Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19 (1997) 453-463 (Pubmed: 9292733)
20. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., and Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J. Neurochem. 97 (2006) 435-448 (Pubmed:16539667)
21. Munger K.A., Montero A., Fukunaga M., Uda S., Yura T., Imai E., Kaneda Y., Valdivielso J.M., and Badr K.F. Transfection of rat kidney with human 15-lipoxygenase suppressed inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13375-13380 (Pubmed: 10557328)
22. Nakajima A., Wada K., Mik H., Kubota N., Nakajima N., Terauchi Y., Ohnishi S., Saubermann L.J., Kadowaki T., Blumberg R.S., Nagai R., and Matsuhashi N. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120 (2001) 460-469 (Pubmed:11159886)
23. Paintlia A.S., Paintlia M.K., Singh I., and Singh A.K. IL-4-induced peroxisome proliferator-activated receptor gamma activation inhibits NF-kappaB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: implication for CNS-demyelinating diseases. J. Immunol. 176 (2006) 4385-4398 (Pubmed: 16547277)
24. Randy L.H., and Guoying B. Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Curr. Neuropharmacol. 5 (2007) 35-46 (Pubmed: 18615152)
25. Remels A.H., Langen R.C., Gosker H.R., Russell A.P., Spaapen F., Voncken J.W., Schrauwen P., and Schols A.M. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 297 (2009) E174-E183 (Pubmed:19417127)
26. Serhan C.N., Jain A., Marleau S., Clish C., Kantarci A., Behbehani B., Colgan S.P., Stahl G.L., Merched A., Petasis N.A., Chan L., and Van Dyke T.E. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171 (2003) 6856-6865 (Pubmed: 14662892)
27. Shen J., Herderick E., Cornhill J.F., Zsigmond E., Kim H.S., Kühn H., Guevara N.V., and Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest. 98 (1996) 2201-2208 (Pubmed: 8941635)
28. Shibuya A., Wada K., Nakajima A., Saeki M., Katayama K., Mayumi T., Kadowaki T., Niwa H., and Kamisaki Y. Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett. 525 (2002) 43-47 (Pubmed:12163159)
29. Smith R.J., Justen J.M., Nidy E.G., Sam L.M., and Bleasdale J.E. Transmembrane signaling in human polymorphonuclear neutrophils: 15(S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid modulates receptor agonist-triggered cell activation. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 7270-7274 (Pubmed: 8394015)
30. Sun L., Ke Y., Zhu C.Y., Tang N., Tian D.K., Gao Y.H., Zheng J.P., and Bian K. Inflammatory reaction versus endogenous PPARs expression, re-exploring secondary organ complications of spontaneously hypertensive rats. Chin. Med. J. (Engl) 121 (2008) 2305-2311 (Pubmed:19080338)
31. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., and Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696 (Pubmed:15590152)
32. van Leyen K., Kim H.Y., Lee S.R., Jin G., Arai K., and Lo E.H. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke 37 (2006) 3014-3018 (Pubmed: 17053180)
33. Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., and Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24 (2006) 1653-1663 (Pubmed:17004929)
34. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim. Biophys. Acta 1128 (1992) 117-131 (Pubmed:1420284)
35. Yi J.H., Park S.W., Brooks N., Lang B.T., and Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 1244 (2008) 164-172 (Pubmed:18948087)
36. Zhao X., Strong R., Zhang J., Sun G., Tsien J.Z., Cui Z., Grotta J.C., and Aronowski J. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J. Neurosci. 29 (2009) 6186-6195 (Pubmed:19439596)
37. Zhao Y., Patzer A., Gohlke P., Herdegen T., and Culman J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. 22 (2005) 278-282 (Pubmed:16029218)